| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Revenue | $29.4M | +59.0% |
| Cost of Revenue | $4.1M | +57.5% |
| Gross Profit | $25.3M | +59.2% |
| R&D Expense | $17.7M | -40.1% |
| SG&A Expense | $18.0M | -23.6% |
| Operating Income | -$36.2M | +33.2% |
| Pre-tax Income | -$30.0M | +49.1% |
| Income Tax | $6K | -33.3% |
| Net Income | -$30.0M |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $8.5M | -27.6% |
| Accounts Receivable | $5.1M | +43.1% |
| Inventory | $4.0M | +59.1% |
| Current Assets | $20.7M | -0.9% |
| Total Assets | $24.0M | -6.8% |
| Current Liabilities | $10.2M | -30.4% |
| Long-term Debt | $22.1M | — |
| Line Item | 2024-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$40.8M | +18.4% |
| Capital Expenditures | $345K | -41.3% |
| Investing Cash Flow | -$345K | +83.7% |
| Financing Cash Flow | $37.9M | -30.6% |
| Free Cash Flow | -$41.2M | +18.7% |
| +49.1% |
| EPS (Basic) | -$1.31 | +80.5% |
| EPS (Diluted) | -$1.31 | +80.5% |
| Total Liabilities |
| $49.9M |
| -3.5% |
| Stockholders' Equity | -$25.9M | +0.2% |